15,241 Shares in PepGen Inc. (NASDAQ:PEPG) Acquired by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in shares of PepGen Inc. (NASDAQ:PEPG) in the 3rd quarter, HoldingsChannel reports. The firm acquired 15,241 shares of the company’s stock, valued at approximately $130,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Suvretta Capital Management LLC increased its stake in shares of PepGen by 9.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after purchasing an additional 140,000 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in PepGen by 11.4% in the second quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company’s stock valued at $8,956,000 after buying an additional 57,504 shares in the last quarter. Janus Henderson Group PLC grew its position in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after acquiring an additional 1,794,641 shares during the last quarter. American Century Companies Inc. raised its stake in PepGen by 19.9% during the second quarter. American Century Companies Inc. now owns 20,028 shares of the company’s stock worth $320,000 after acquiring an additional 3,326 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of PepGen in the second quarter worth about $192,000. 58.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PEPG shares. Wedbush decreased their price target on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of PepGen in a research note on Friday, November 8th. Finally, Bank of America cut PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research note on Monday, December 16th.

PepGen Price Performance

PepGen stock opened at $3.63 on Friday. The business has a 50 day moving average of $5.96 and a 200-day moving average of $10.33. PepGen Inc. has a 1 year low of $2.90 and a 1 year high of $19.30. The company has a market capitalization of $118.32 million, a P/E ratio of -1.22 and a beta of 1.56.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.